Abstract
Quantitative real time PCR was performed on genomic DNA from 40 primary oral carcinomas and the normal adjacent tissues. The target genes ECGFB, DIA1, BIK, and PDGFB and the microsatellite markers D22S274 and D22S277, mapped on 22q13, were selected according to our previous loss of heterozygosity findings in head and neck tumors. Quantitative PCR relies on the comparison of the amount of product generated from a target gene and that generated from a disomic reference gene (GAPDH-housekeeping gene). Reactions have been performed with normal control in triplicates, using the 7700 Sequence Detection System (PE Applied Biosystems). Losses in the sequences D22S274 (22q13.31) and in the DIA1 (22q13.2–13.31) gene were detected in 10 out of 40 cases (25%) each. Statistically significant correlations were observed for patients with relative copy number loss of the marker D22S274 and stages T3–T4 of disease (P=0.025), family history of cancer (P=0.001), and death (P=0.021). Relative copy number loss involving the DIA1 gene was correlated to family history of cancer (P<0.001), death (P=0.002), and consumption of alcohol (P=0.026). Log-rank test revealed a significant decrease in survival (P=0.0018) for patients with DIA1 gene loss. Relative copy number losses detected in these sequences may be related to disease progression and a worse prognosis in patients with oral cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
AJCC. 1998 American Joint Committee on Cancer Cancer Staging Handbook, AJCC cancer staging manual 5th edn GB Lippincott-Raven (ed)
Bérgamo NA, Rogatto SR, Poli-Frederico RC, Reis PP, Kowalski LP, Zielenska M, Squire JA . 2000 Cancer Genet. Cytogenet. 119: 48–55
Bièche I, Olivi M, Champème M-H, Vidaud D, Lidereau R, Vidaud M . 1998 Int. J. Cancer 78: 661–666
Biegel JA, Fogrelgen B, Wainwright LM, Zhou JY, Bevan H, Rorke LB . 2000 Genes Chromosomes Cancer 28: 31–37
Blancato JK . 1999 In The principles of clinical cytogenetics Steven L Gersen and Martha B Keagle (eds) New Jersey: Humana Press pp 443–471
Bockmühl U, Wolf G, Schmidt S, Schwendel A, Jahnke V, Dietel M, Petersen I . 1998 Head Neck 20: 145–154
Boyd JM, Gallo GL, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RL . 1995 Oncogene 11: 1921–1928
Bryan E, Thomas NA, Palmer K, Dawson E, Englefield P, Campbell IG . 2000 Int. J. Cancer 87: 798–802
Bustin SA . 2000 J. Mol. Endocrinol. 25: 169–193
Castells A, Ino Y, Louis DN, Ramesh V, Gusella JF . 1999 Gastroenterol. 117: 831–837
Cortesina G, Martone T, Galeazzi E, Olivero M, De Stefani A, Bussi M, Valente G, Comoglio PM, Di Renzo MF . 2000 Int. J. Cancer 89: 286–292
Dracopoli NC . 2000 Current Protocols in Human Genetics New York: John Wiley and Sons
Englefield P, Foulkes WD, Campbell IG . 1994 Br. J. Cancer 70: 905–907
Goff LK, Neat MJ, Crawley CR, Jones L, Jones E, Lister TA, Gupta RK . 2000 Br. J. Haematol. 111: 618–625
Grati FR, Sirchia AM, Garagiola I, Sironi E, Galioto S, Rossella F, Serafini P, Dulcetti F, Bozzetti A, Brusati R, Simoni G . 2000 Cancer Genet. Cytogenet. 118: 57–61
Hagiwara K, Stenman G, Honda H, Sahlin P, Andersson A, Miyazono K, Heldin CH, Ishikawa F, Takaku F . 1991 Mol. Cell Biol. 11: 2125–2132
Helenius MA, Saramaki OR, Linja MJ, Tammela TL, Visakorpi T . 2001 Cancer Res. 61: 5340–5344
Josephs SF, Ratner L, Clarke MF, Westin EH, Reitz MS, Wong-Staal F . 1984 Science 225: 636–639
Kim N-G, Kim JJ, Ahn J-Y, Seong C-M, Noh SH, Kim CB, Min JS, Kim H . 2000 Int. J. Cancer 85: 633–638
Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M . 2000 Genes Chromosomes Cancer 27: 244–251
Lehmann U, Glöckner S, Kleeberger W, Feist H, Von Wasielewski R, Kreipe H . 2000 Am. J. Pathol. 156: 1855–1864
Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ . 2000 Cancer Res. 60: 6878–6881
Loeb KR, Loeb LA . 2000 Carcinogenesis 21: 379–385
Miyakawa A, Wang X-L, Nakanishi H, Imai FL, Shiiba M, Miya T, Imai Y, Tanzawa H . 1998 Int. J. Oncol. 13: 705–709
Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, Robison JG, Metcalf JS, Palesch YY, Zhang Z, Gillanders WE, Cole DJ . 2001 Int. J. Cancer 93: 162–171
Nakanishi H, Kodera Y, Yamamura Y, Ito S, Kato T, Ezaki T, Tatematsu M . 2000 Int. J. Cancer (Pred. Oncol.) 89: 411–417
Oskam NT, Bijleveld EH, Hulsebos TJM . 2000 Int. J. Cancer 85: 336–339
Peter M, Gilbert E, Delattre O . 2001 Lab. Invest. 81: 905–912
Poli-Frederico RC, Bérgamo NA, Reis PP, Kowalski LP, Zielenska M, Squire JA, Rogatto SR . 2000 Head Neck 22: 585–590
Quon H, Liu FF, Cummings BJ . 2001 Head Neck 23: 147–159
Reis PP, Poli-Frederico RC, Santos RM, Nishimoto IN, Kowalski LP, Rogatto SR . 2002 Med. Sci. Monit. 8: BR89–BR94
Renan MJ . 1993 Mol. Carcinogenesis 7: 139–146
Rogatto SR, Rainho CA, Zhang ZM, Figueiredo F, Barbieri-Neto J, Georgetto SM, Squire JA . 1999 Cancer Genet. Cytogenet. 110: 23–27
Ruiz-Ponte C, Loidi L, Vega A, Carracedo A, Barros F . 2000 Clin. Chem. 46: 1574–1582
Shin E, Fujita S, Takami K, Kurahashi H, Kurita Y, Kobayashi T, Mori T, Nishisho I, Takai S . 1993 Jpn. J. Cancer Res. 84: 402–408
Simpson DAC, Feeney S, Boyle C, Stitt AW . 2000 Mol. Vision 6: 178–183
Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hennen G, Grisar T, Igout A, Heinen E . 1999 J. Biotecnol. 75: 291–295
Twist EC, Ruttledge MH, Rousseau M . 1995 Hum. Mol. Genet. 3: 147–151
Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T . 1999 Cancer Res. 59: 5995–5998
Vokes EE, Weichselbaum RR, Lippman SM, Hong WK . 1993 N. Engl. J. Med. 328: 184–194
Wight AJ, Ogden GR . 1998 Oral Oncol. 34: 441–447
World Health Organization. 1990 International classification of diseases for oncology 2nd edn Geneva: World Health Organization
Acknowledgements
We would like to thank Ben Beheshti for the informatics assistance, and to Dr Juan A Rey (Madrid, Spain) and Dr Maria Zielenska (Toronto, ON, Canada) for supplying the pEFZ31 and the BAC RPI222E13 clones, respectively. The authors acknowledge FAPESP and CNPq for financial support and the Conacher Cancer Research Fund of the University Health Network, Toronto, Ontario, Canada.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reis, P., Rogatto, S., Kowalski, L. et al. Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene 21, 6480–6487 (2002). https://doi.org/10.1038/sj.onc.1205864
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205864
Keywords
This article is cited by
-
Genetic and epigenetic characterization of the tumors in a patient with a tongue primary tumor, a recurrence and a pharyngoesophageal second primary tumor
Molecular Cytogenetics (2017)
-
BH3-only proteins in apoptosis and beyond: an overview
Oncogene (2008)
-
BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes
Oncogene (2008)
-
Evidence of functional interaction between NuMA-RARα and RXRα in an in vivo model of acute promyelocytic leukemia
Oncogene (2008)
-
Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas
Laboratory Investigation (2005)